SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $709,868 | -74.0% | 48,889 | -62.6% | 0.00% | -66.7% |
| Q2 2023 | $2,733,835 | +18.5% | 130,618 | +19.6% | 0.00% | 0.0% |
| Q1 2023 | $2,306,219 | -4.1% | 109,196 | +15.5% | 0.00% | 0.0% |
| Q4 2022 | $2,405,356 | +5.9% | 94,513 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $2,271,147 | +513.8% | 94,513 | +391.7% | 0.00% | +200.0% |
| Q2 2022 | $370,000 | +19.7% | 19,220 | +8.0% | 0.00% | 0.0% |
| Q1 2022 | $309,000 | -20.6% | 17,793 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $389,000 | +14.4% | 17,793 | -0.0% | 0.00% | 0.0% |
| Q3 2021 | $340,000 | -88.6% | 17,797 | -89.7% | 0.00% | -83.3% |
| Q2 2021 | $2,973,000 | -12.3% | 173,086 | +14.1% | 0.01% | -14.3% |
| Q1 2021 | $3,391,000 | -12.4% | 151,646 | -12.9% | 0.01% | -12.5% |
| Q4 2020 | $3,872,000 | +2973.0% | 174,103 | +1410.3% | 0.01% | – |
| Q1 2020 | $126,000 | +24.8% | 11,528 | 0.0% | 0.00% | – |
| Q4 2019 | $101,000 | – | 11,528 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |